Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2023-08-25

FDA Approved: LISDEXAMFETAMINE DIMESYLATE — Original Application (Rhodes Pharmaceuticals)

View source ↗

Summary

FDA approved an original generic application for lisdexamfetamine dimesylate from Rhodes Pharmaceuticals for the treatment of ADHD and binge eating disorder.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • LISDEXAMFETAMINE DIMESYLATE (Lisdexamfetamine dimesylate)

Snippet

ORIG AP for LISDEXAMFETAMINE DIMESYLATE (LISDEXAMFETAMINE DIMESYLATE)